Company intelligence / Profile preview
ABL Bio
Seongnam-si, South Koreaablbio.com ↗
- Ownership
- Public · 298380
- Employees
- ~102
- Development stage
- Other
01
Overview
ABL Bio has multiple clinical and pre-clinical stage drug candidates. ABL001 (tovecimig) has been granted Fast Track designation by the FDA. The company has a Phase 1b/2a clinical study for ABL001 in oncology.
- Therapeutic areas
- OncologyNeurology
- Modalities
- Bispecific antibodiesAntibody-drug conjugates (ADC)
- Industry
- Biotech
02
Drug pipeline
15 assets14 more assets in the full pipeline.
03
Partnerships
04
Financials
- Market cap
- $1.5B
- Total revenue
- $58.6M
- Enterprise value
- $1.4B
Beyond the preview
Go deeper on ABL Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ABL Bio.